The Mitral Valve Heart Team

  • David Messika-ZeitounEmail author
  • Anthony Tran
  • Benjamin Hibbert
  • Vincent Chan


The field of cardiac surgery has drastically changed over the course of half a century. With the implementation of advanced catheter-based techniques, less invasive surgical methods, and generally a sicker population of patients, came a necessary collaboration between disciplines. We have seen this in the treatment of ischemic heart disease and now aortic valve disease. Mitral valve surgery presents a unique population of patients that are both complex and heterogeneous in their pathology. The pathophysiology of these patients may be primarily valvular in origin or secondary to ventricular failure (i.e. functional). In order to determine the safest, most efficacious, and most durable treatment, it is necessary to have a heart team dedicated to the practice. Expertise from cardiologist, interventionalist, advanced anesthesiologist and additional fields become increasingly necessary. The care for this patient population only begins with their evaluation before the invention and endures long after. The literature has demonstrated a disparity in knowledge on the pathophysiology as well as optimal treatment for this cohort. Moreover, the creation of a mitral valve heart team will face significant challenges requiring a change in practitioner culture and even referral pattern. Nevertheless, sharing information between disciplines with an ultimate goal of how best to manage this complex disease is in the foreseeable future. Tracking outcomes and benchmarking institutions with mitral valve heart teams will become the norm.


Mitral valve (MV) disease Left ventricular ejection fraction (LVEF) Mitral valve regurgitation (MR) Echocardiography Transcatheter intervention Incremental cost-effectiveness ratio (ICER) 


  1. 1.
    Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–11.CrossRefGoogle Scholar
  2. 2.
    Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.CrossRefGoogle Scholar
  3. 3.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(25):e1159–95.CrossRefGoogle Scholar
  4. 4.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(23):2440–92.CrossRefGoogle Scholar
  5. 5.
    Lang RM, Addetia K, Narang A, Mor-Avi V. 3-dimensional echocardiography: latest developments and future directions. JACC Cardiovasc Imaging. 2018;11(12):1854–78.CrossRefGoogle Scholar
  6. 6.
    Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303–71.CrossRefGoogle Scholar
  7. 7.
    Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005;352(9):875–83.CrossRefGoogle Scholar
  8. 8.
    El-Tallawi KC, Messika-Zeitoun D, Zoghbi WA. Assessment of the severity of native mitral valve regurgitation. Prog Cardiovasc Dis. 2017;60(3):322–33.CrossRefGoogle Scholar
  9. 9.
    Verma S, Mesana TG. Mitral-valve repair for mitral-valve prolapse. N Engl J Med. 2009;361(23):2261–9.CrossRefGoogle Scholar
  10. 10.
    Braunberger E, Deloche A, Berrebi A, Abdallah F, Celestin JA, Meimoun P, et al. Very long-term results (more than 20 years) of valve repair with carpentier’s techniques in nonrheumatic mitral valve insufficiency. Circulation. 2001;104(12 Suppl 1):I8–11.CrossRefGoogle Scholar
  11. 11.
    Chan V, Ruel M, Chaudry S, Lambert S, Mesana TG. Clinical and echocardiographic outcomes after repair of mitral valve bileaflet prolapse due to myxomatous disease. J Thorac Cardiovasc Surg. 2012;143(4 Suppl):S8–11.CrossRefGoogle Scholar
  12. 12.
    Chikwe J, Toyoda N, Anyanwu AC, Itagaki S, Egorova NN, Boateng P, et al. Relation of mitral valve surgery volume to repair rate, durability, and survival. J Am Coll Cardiol. 2017:pii:S0735-1097(17)30677-0.Google Scholar
  13. 13.
    Gammie JS, O’Brien SM, Griffith BP, Ferguson TB, Peterson ED. Influence of hospital procedural volume on care process and mortality for patients undergoing elective surgery for mitral regurgitation. Circulation. 2007;115(7):881–7.CrossRefGoogle Scholar
  14. 14.
    Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364(15):1395–406.CrossRefGoogle Scholar
  15. 15.
    Messika-Zeitoun D, Nickenig G, Latib A, Kuck KH, Baldus S, Schueler R, et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. Eur Heart J. 2019;40(5):466–72.CrossRefGoogle Scholar
  16. 16.
    Sorajja P, Mack M, Vemulapalli S, Holmes DR Jr, Stebbins A, Kar S, et al. Initial experience with commercial transcatheter mitral valve repair in the United States. J Am Coll Cardiol. 2016;67(10):1129–40.CrossRefGoogle Scholar
  17. 17.
    Nguyen V, Michel M, Eltchaninoff H, Gilard M, Dindorf C, Iung B, et al. Implementation of transcatheter aortic valve replacement in France. J Am Coll Cardiol. 2018;71(15):1614–27.CrossRefGoogle Scholar
  18. 18.
    Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med. 2013;370(1):23–32.CrossRefGoogle Scholar
  19. 19.
    Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med. 2015;374(4):344–53.CrossRefGoogle Scholar
  20. 20.
    Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379(24):2297–306.CrossRefGoogle Scholar
  21. 21.
    Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014;371(23):2178–88.CrossRefGoogle Scholar
  22. 22.
    Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379(24):2307–18.CrossRefGoogle Scholar
  23. 23.
    Barbieri A, Bursi F, Grigioni F, Tribouilloy C, Avierinos JF, Michelena HI, et al. Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. Eur Heart J. 2011;32(6):751–9.CrossRefGoogle Scholar
  24. 24.
    Enriquez-Sarano M, Suri RM, Clavel MA, Mantovani F, Michelena HI, Pislaru S, et al. Is there an outcome penalty linked to guideline-based indications for valvular surgery? Early and long-term analysis of patients with organic mitral regurgitation. J Thorac Cardiovasc Surg. 2015;150(1):50–8.CrossRefGoogle Scholar
  25. 25.
    Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos JF, et al. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA. 2013;310(6):609–16.CrossRefGoogle Scholar
  26. 26.
    Tribouilloy C, Rusinaru D, Grigioni F, Michelena HI, Vanoverschelde JL, Avierinos JF, et al. Long-term mortality associated with left ventricular dysfunction in mitral regurgitation due to flail leaflets: a multicenter analysis. Circ Cardiovasc Imaging. 2014;7(2):363–70.CrossRefGoogle Scholar
  27. 27.
    Dziadzko V, Clavel MA, Dziadzko M, Medina-Inojosa JR, Michelena H, Maalouf J, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391(10124):960–9.CrossRefGoogle Scholar
  28. 28.
    Iung B, Delgado V, Lazure P, Murray S, Sirnes PA, Rosenhek R, et al. Educational needs and application of guidelines in the management of patients with mitral regurgitation. A European mixed-methods study. Eur Heart J. 2018;39(15):1295–303.CrossRefGoogle Scholar
  29. 29.
    Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16(1):9–13.CrossRefGoogle Scholar
  30. 30.
    Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41(4):734–44.CrossRefGoogle Scholar
  31. 31.
    O’Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery. Ann Thorac Surg. 2009;88(1 Suppl):S23–42.CrossRefGoogle Scholar
  32. 32.
    Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999;15(6):816–22.CrossRefGoogle Scholar
  33. 33.
    Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Detaint D, Vanoverschelde JL, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007;28(11):1358–65.CrossRefGoogle Scholar
  34. 34.
    Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, et al. ESC working group on valvular heart disease position paper—heart valve clinics: organization, structure, and experiences. Eur Heart J. 2013;34(21):1597–606.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • David Messika-Zeitoun
    • 1
    Email author
  • Anthony Tran
    • 2
  • Benjamin Hibbert
    • 3
  • Vincent Chan
    • 4
  1. 1.Division of CardiologyUniversity of Ottawa Heart InstituteOttawaCanada
  2. 2.University of Connecticut Health, Department of SurgeryFarmingtonUSA
  3. 3.Department of Medicine, Division of CardiologyUniversity of Ottawa Heart InstituteOttawaCanada
  4. 4.Department of SurgeryUniversity of Ottawa Heart InstituteOttawaCanada

Personalised recommendations